KKR, a prominent global investment firm, has announced the acquisition of Healthium Medtech Ltd., a top-tier Indian medical devices company. The transaction, facilitated by funds managed by KKR, involves the purchase from an affiliate of Apax Partners LLP, a distinguished global private equity advisory firm.
Healthium, established in 1992, has been at the forefront of developing and marketing an extensive array of surgical products worldwide. The company’s diverse and high-quality product range addresses various surgical needs, including wound closure, arthroscopy, and advanced wound care solutions.
The strategic acquisition by KKR is set to be executed through a special purpose vehicle, which will secure a controlling stake in the Healthium group. This move marks a pivotal transition for Healthium, which was acquired by Apax Funds in 2018. Under Apax’s guidance, Healthium evolved from a domestic entity into a global MedTech leader, expanding its market presence from 50 to over 90 countries.
KKR’s investment, drawn from its Asian Fund IV, underscores the firm’s commitment to the healthcare sector across India and the Asia Pacific region. Healthium joins KKR’s impressive portfolio, which includes JB Pharmaceuticals, Max Healthcare, Gland Pharma, PHC in Japan, Bushu Pharma, and Metro Pacific Hospitals in the Philippines.
The deal, poised to close in the third quarter of 2024, awaits regulatory approval. While financial specifics remain undisclosed, the acquisition heralds a new era of growth and innovation for Healthium, propelled by KKR’s extensive global network and deep healthcare industry expertise.
Both Apax Partners and Healthium received advisory services from Jefferies LLC and Kirkland & Ellis LLP, respectively. KKR’s counsel comprised Moelis & Company, Simpson Thacher & Bartlett, and AZB & Partners.